MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States. Its lead product candidate includes AFREZZA inhalation powder, an insulin that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. The company also develops MedTone and Dreamboat inhaler devices. MannKind Corporation was founded in 1991 and is headquartered in Valencia, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool

• [07/08/2014 22:15 PDT] MNKD Expected To Be Down Before Next Earnings Releases
• [07/21/2014 05:13 PDT] MNKD, Expected to Trade Lower After Bearish Insider Trading
• [07/08/2014 22:15 PDT] Mannkind Corp (NASDAQ:MNKD), Down By 5.37% ($0.52) From $9.690 After BUYINS.NET Report Predicted Weakness Before Earnings
• [07/07/2014 05:35 PDT] MNKD, Expected to Trade Lower After Bearish Insider Trading
• [07/02/2014 05:04 PDT] Mannkind Corp (NASDAQ:MNKD), Down By 5.91% ($0.61) From $10.320 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [07/02/2014 05:04 PDT] MNKD, Expected to Trade Lower After Bearish Insider Trading
• [07/01/2014 17:45 PDT] Market Maker Surveillance Report. MNKD, Highest Net Sell Volume and Negative Price Friction For Tuesday, July 1st 2014
• [06/11/2014 06:00 PDT] MNKD, Added To Naked Short Lists Today
• [06/19/2014 05:16 PDT] MNKD, Expected to Trade Lower After Bearish Insider Trading
• [06/18/2014 06:00 PDT] MNKD, Removed From Naked Short Lists Today
• [06/09/2014 05:52 PDT] MNKD, Expected to Trade Lower After Bearish Insider Trading
• [06/04/2014 17:45 PDT] Market Maker Surveillance Report. MNKD, Highest Net Buy Volume With Lowest Price Friction For Wednesday, June 4th 2014